These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35596929)

  • 1. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease.
    Hartl L; Haslinger K; Angerer M; Semmler G; Schneeweiss-Gleixner M; Jachs M; Simbrunner B; Bauer DJM; Eigenbauer E; Strassl R; Breuer M; Kimberger O; Laxar D; Lampichler K; Halilbasic E; Stättermayer AF; Ba-Ssalamah A; Mandorfer M; Scheiner B; Reiberger T; Trauner M
    Hepatology; 2022 Dec; 76(6):1563-1575. PubMed ID: 35596929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary Sclerosing Cholangitis due to Severe COVID-19: An Emerging Disease Entity?
    Seifert M; Kneiseler G; Dechene A
    Digestion; 2023; 104(4):306-312. PubMed ID: 36889285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19.
    Bütikofer S; Lenggenhager D; Wendel Garcia PD; Maggio EM; Haberecker M; Reiner CS; Brüllmann G; Buehler PK; Gubler C; Müllhaupt B; Jüngst C; Morell B
    Liver Int; 2021 Oct; 41(10):2404-2417. PubMed ID: 34018314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients.
    Hartl L; Haslinger K; Angerer M; Jachs M; Simbrunner B; Bauer DJM; Semmler G; Scheiner B; Eigenbauer E; Strassl R; Breuer M; Kimberger O; Laxar D; Trauner M; Mandorfer M; Reiberger T
    Liver Int; 2022 Jun; 42(6):1297-1307. PubMed ID: 35412018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of COVID-19 on patients with compensated chronic liver diseases.
    Ji D; Zhang D; Yang T; Mu J; Zhao P; Xu J; Li C; Cheng G; Wang Y; Chen Z; Qin E; Lau G
    Hepatol Int; 2020 Sep; 14(5):701-710. PubMed ID: 32734407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).
    Sarin SK; Choudhury A; Lau GK; Zheng MH; Ji D; Abd-Elsalam S; Hwang J; Qi X; Cua IH; Suh JI; Park JG; Putcharoen O; Kaewdech A; Piratvisuth T; Treeprasertsuk S; Park S; Wejnaruemarn S; Payawal DA; Baatarkhuu O; Ahn SH; Yeo CD; Alonzo UR; Chinbayar T; Loho IM; Yokosuka O; Jafri W; Tan S; Soo LI; Tanwandee T; Gani R; Anand L; Esmail ES; Khalaf M; Alam S; Lin CY; Chuang WL; Soin AS; Garg HK; Kalista K; Batsukh B; Purnomo HD; Dara VP; Rathi P; Al Mahtab M; Shukla A; Sharma MK; Omata M;
    Hepatol Int; 2020 Sep; 14(5):690-700. PubMed ID: 32623632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent Cholestatic Injury and Secondary Sclerosing Cholangitis in COVID-19 Patients.
    Shih AR; Hatipoglu D; Wilechansky R; Goiffon R; Deshpande V; Misdraji J; Chung RT
    Arch Pathol Lab Med; 2022 Oct; 146(10):1184-1193. PubMed ID: 35657750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe acute respiratory syndrome coronavirus-2-associated cholangiopathies.
    Bartoli A; Cursaro C; Andreone P
    Curr Opin Gastroenterol; 2022 Mar; 38(2):89-97. PubMed ID: 35098930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease.
    Duengelhoef P; Hartl J; Rüther D; Steinmann S; Brehm TT; Weltzsch JP; Glaser F; Schaub GM; Sterneck M; Sebode M; Weiler-Normann C; Addo MM; Lütgehetmann M; Haag F; Schramm C; Schulze Zur Wiesch J; Lohse AW
    United European Gastroenterol J; 2022 Apr; 10(3):319-329. PubMed ID: 35289983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
    Marjot T; Moon AM; Cook JA; Abd-Elsalam S; Aloman C; Armstrong MJ; Pose E; Brenner EJ; Cargill T; Catana MA; Dhanasekaran R; Eshraghian A; García-Juárez I; Gill US; Jones PD; Kennedy J; Marshall A; Matthews C; Mells G; Mercer C; Perumalswami PV; Avitabile E; Qi X; Su F; Ufere NN; Wong YJ; Zheng MH; Barnes E; Barritt AS; Webb GJ
    J Hepatol; 2021 Mar; 74(3):567-577. PubMed ID: 33035628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic Fatty Liver Disease and COVID-19 Susceptibility and Outcomes: a Korean Nationwide Cohort.
    Yoo HW; Jin HY; Yon DK; Effenberger M; Shin YH; Kim SY; Yang JM; Kim MS; Koyanagi A; Jacob L; Smith L; Yoo IK; Shin JI; Lee SW
    J Korean Med Sci; 2021 Oct; 36(41):e291. PubMed ID: 34697932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic failure after injury - a common pathogenesis with sclerosing cholangitis?
    Zilkens C; Friese J; Köller M; Muhr G; Schinkel C
    Eur J Med Res; 2008 Jul; 13(7):309-13. PubMed ID: 18700186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease.
    Mak LY; Chung MSH; Li X; Lai FTT; Wan EYF; Chui CSL; Cheng FWT; Chan EWY; Cheung CL; Au ICH; Xiong X; Seto WK; Yuen MF; Wong CKH; Wong ICK
    World J Hepatol; 2024 Feb; 16(2):211-228. PubMed ID: 38495273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Liver Disease and Cirrhosis are Associated with Worse Outcomes Following SARS-CoV-2 Infection.
    Wong RJ; Zhang Y; Thamer M
    J Clin Exp Hepatol; 2023; 13(4):592-600. PubMed ID: 36777086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19-associated secondary sclerosing cholangitis - A case series of 4 patients.
    Ferreira FB; Mourato M; Bragança S; Paulo JB; Sismeiro R; Pereira A; Mónica AN; Lourenço LC; Cardoso M
    Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102048. PubMed ID: 36347499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19-associated secondary sclerosing cholangitis with liver transplantation.
    Fischer AK; Stippel D; Canbay A; Nierhoff D; Thomas M; Best J; Büttner R; Drebber U
    Virchows Arch; 2024 Aug; 485(2):371-377. PubMed ID: 38526652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 infection in patients with autoimmune hepatitis.
    Marjot T; Buescher G; Sebode M; Barnes E; Barritt AS; Armstrong MJ; Baldelli L; Kennedy J; Mercer C; Ozga AK; Casar C; Schramm C; ; Moon AM; Webb GJ; Lohse AW
    J Hepatol; 2021 Jun; 74(6):1335-1343. PubMed ID: 33508378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of mortality in people with chronic liver diseases hospitalized for Coronavirus disease of 2019 (COVID-19) in a tertiary hospital in Lombardy, Italy.
    Ranzenigo M; Ceccarelli D; Galli L; Bertoni C; Siribelli A; Messina E; Hasson H; Lolatto R; Castagna A; Uberti-Foppa C; Morsica G
    New Microbiol; 2023 Sep; 46(3):296-302. PubMed ID: 37747475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver manifestations in COVID-19 and the influence of pre-existing liver disease in the course of the infection.
    Guerra Veloz MF; Cordero Ruiz P; Ríos-Villegas MJ; Del Pino Bellido P; Bravo-Ferrer J; Galvés Cordero R; Cadena Herrera ML; Vías Parrado C; Bellido Muñoz F; Vega Rodríguez F; Caunedo Álvarez Á; Rodríguez-Baño J; Carmona Soria I
    Rev Esp Enferm Dig; 2021 Feb; 113(2):103-109. PubMed ID: 33393329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Liver Test Abnormalities and Chronic Liver Disease on the Clinical Outcomes of Patients Hospitalized with COVID-19.
    Garrido M; Pereira Guedes T; Alves Silva J; Falcão D; Novo I; Archer S; Rocha M; Maia L; Sarmento-Castro R; Pedroto I
    GE Port J Gastroenterol; 2021 Jan; 158(4):1-12. PubMed ID: 34192127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.